•Eligible commercially insured patients may pay as little as $0 per dose
•Maximum benefit of $14,000 per calendar year
•Maximum saving limit applies; patient outofpocket expense may vary on a monthly, quarterly, and/or annual basis depending on each individual patient’s plan of insurance and other prescription drug costs
•Benefit covers all approved indications for Skyrizi; for psoriatic arthritis patients, the benefit covers SKYRIZI plus one of the following medications: methotrexate, leflunomide, or hydroxychloroquine
•For Crohn’s disease patients, this benefit covers SKYRIZI alone or for SKYRIZI with product associated infusion (maximum savings limit of $1,000 per year applies) and eligible liver enzyme and bilirubin lab monitoring costs (maximum savings limit of $1,000 per year applies) where the full cost is not covered by a patient’s insurance
•For Crohn's disease ONLY: Patient or healthcare provider is required to submit an Explanation of Benefits (EOB) following each infusion and/or laboratory test to the CoPay Program
•Crohn's patients: Online rebate submission: https://www.skyrizi.com/skyrizicomplete/crohns/labrebates
•Skyrizi Infusion Reimbursement Options and Fax form for Crohn's patients: https://www.skyrizihcp.com/content/dam/skyrizihcpivy/docs/reimbursementoptionsform.pdf
•Reimbursement support (Crohn's patients): 8772667538 or 8004710186 option 5
•If AbbVie determines that you are subject to a copay maximizer program, (even if the patient is unaware of the fact), except where prohibited by applicable state law, AbbVie may discontinue the availability of copay support at an amount not to exceed $4,000